Compare · ABT vs MPLT
ABT vs MPLT
Side-by-side comparison of Abbott Laboratories (ABT) and MapLight Therapeutics Inc. (MPLT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and MPLT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $182.59B, about 299.9x MPLT ($608.9M).
- ABT has been more active in the news (10 items in the past 4 weeks vs 7 for MPLT).
- ABT has more recent analyst coverage (25 ratings vs 14 for MPLT).
- Company
- Abbott Laboratories
- MapLight Therapeutics Inc.
- Price
- -
- -
- Market cap
- $182.59B
- $608.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 10
- 7
- Recent ratings
- 25
- 14
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
- VICE PRESIDENT AND CONTROLLER Mccoy John A. Jr. covered exercise/tax liability with 52 units of Common shares without par value and sold $2,958 worth of Common shares without par value (27 units at $109.54), decreasing direct ownership by 0.32% to 24,549 units (SEC Form 4)
- EVP AND CFO Boudreau Philip P covered exercise/tax liability with 388 units of Common shares without par value, decreasing direct ownership by 0.55% to 70,784 units (SEC Form 4)
- Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula
- CHAIRMAN AND CEO Ford Robert B exercised 398,832 units of Common shares without par value at a strike of $54.02 and sold $46,204,798 worth of Common shares without par value (398,832 units at $115.85) (SEC Form 4)
- Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
Latest MPLT
- Chief Discovery Officer Kreitzer Anatol was granted 6,020 units of Voting Common Stock, increasing direct ownership by 3% to 180,926 units (SEC Form 4)
- CAO and Interim CFO Gillis Jonathan was granted 8,242 units of Voting Common Stock, increasing direct ownership by 6% to 152,482 units (SEC Form 4)
- Chief Executive Officer Kroeger Christopher A. was granted 23,145 units of Voting Common Stock, increasing direct ownership by 2% to 1,269,600 units (SEC Form 4)
- General Counsel Hanson Kristopher was granted 7,730 units of Voting Common Stock, increasing direct ownership by 5% to 153,553 units (SEC Form 4)
- Chief Medical Officer Foff Erin Pennock was granted 13,360 units of Voting Common Stock, increasing direct ownership by 4% to 312,261 units (SEC Form 4)
- Chief Scientific Officer Lillie James Woodruff was granted 7,730 units of Voting Common Stock, increasing direct ownership by 4% to 210,110 units (SEC Form 4)
- Large owner Catalyst4, Inc. bought $50,072,000 worth of Voting Common Stock (4,400,000 units at $11.38) (SEC Form 4)
- SEC Form 10-Q filed by MapLight Therapeutics Inc.
- MapLight Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure
- MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update